www.projectcork.org
A comparative review of best practice guidelines
for the diversion of drug related offenders.
(review).
Bull M. International Journal of Drug Policy 16(4):
223-234, 2005. (77 refs.)
In recent decades rates of imprisonment have
increased throughout the industrialised world as has
the proportion of people whose imprisonment is linked
to their use of illicit drugs. While the relationship
between drug use and crime remains unclear, it has
been argued that punitive responses alone are
unsuccessful in reducing illegal drug use and
associated crime. Disillusionment with traditional
criminal justice approaches to drug-using offenders
has renewed interest in programmes diverting drug
related offenders from the criminal justice system. In
the 1990s a number of diversion best practice
guidelines became available, largely preceding the
emerging evaluation literature. This represents a
challenge for policy makers committed to evidencebased standards of best practice. This paper is a
comparative analysis of best practice guidelines for
various diversionary programmes delivered in
different parts of the world. Consistent themes running
through the guidelines and the relationship between
these themes and the available evaluation literature
were identified. The results of this qualitative metaanalysis suggest that sufficient evidence exists to
support the principles outlined in these guidelines.
Copyright 2005, Elsevier Science BV.
Collaboration between child welfare and substanceabuse fields: Combined treatment programs for
mothers. (review).
Kerwin ME. Journal of Pediatric Psychology 30(7):
581-597, 2005. (125 refs.)
Objective: To review collaboration between child
welfare and drug-abuse fields in providing treatment to
mothers who abuse drugs and maltreat their children.
Methods: Literature review of studies examining
effects of maternal drug abuse on parenting skills and
outcomes of interventions for both maternal drug
abuse and parenting skills. Results: Parenting skills
differ between mothers who do and do not abuse
drugs, but these studies are primarily limited to
mothers of infants and preschoolers. The evidence
base for interventions to address both substance use
substance abuse
review articles
Winter 2006
page 2
Delta-9-tetrahydrocannabinol effects in
schizophrenia: Implications for cognition,
psychosis, and addiction. (review).
D'Souza DC; Abi-Saab WM; Madonick S; ForseliusBielen K; Doersch A et al. Biological Psychiatry
57(6): 594-608, 2005. (158 refs.)
BACKGROUND:
Recent
advances
in
the
neurobiology of cannabinoids have renewed interest in
the association between cannabis and psychotic
disorders. METHODS: In a 3-day, double-blind,
randomized, placebo-controlled study, the behavioral,
cognitive, motor, and endocrine effects of 0 mg, 2.5
mg, and 5 mg intravenous Delta-9-tetrahydrocannabinol (Delta-9-THC) were characterized in 13
stable, antipsychotic-treated schizophrenia patients.
These data were compared with effects in healthy
subjects reported elsewhere. RESULTS: Delta-9tetrahydrocannabinol transiently increased 1) learning
and recall deficits; 2) positive, negative, and general
schizophrenia symptoms; 3) perceptual alterations; 4)
akathisia, rigidity, and dyskinesia; 5) deficits in
vigilance; and 6) plasma prolactin and cortisol.
Schizophrenia patients were more vulnerable to Delta9-THC effects on recall relative to control subjects.
There were no serious short- or long-term adverse
events
associated
with
study
participation.
CONCLUSIONS: Delta-9-tetrahydrocannabinol is
associated with transient exacerbation in core
psychotic and cognitive deficits in schizophrenia.
These data do not provide a reason to explain why
schizophrenia patients use or misuse cannabis.
Furthermore, Delta-9-THC might differentially affect
schizophrenia patients relative to control subjects.
Finally, the enhanced sensitivity to the cognitive
page 3
page 4
Cochrane Reviews
Benzodiazepines for alcohol withdrawal. (review).
Ntais C; Pakos E; Kyzas P; Ioannidis JPA. Cochrane
Database of Systemic Reviews (3): CD005063.pub2,
2005. (94 refs.)
Objectives To evaluate the effectiveness and safety of
benzodiazepines in the treatment of alcohol
withdrawal. Main results Fifty-seven trials, with a total
of 4,051 people were included. Benzodiazepines
offered a large benefit against alcohol withdrawal
seizures compared to placebo. Authors ' conclusions
Benzodiazepines are effective against alcohol
withdrawal symptoms, in particular seizures, when
compared to placebo. It is not possible to draw definite
conclusions about the relative effectiveness and safety
of benzodiazepines against other drugs in alcohol
withdrawal, but the available data do not show
prominent differences between benzodiazepines and
other drugs in success rates. Copyright 2005, Wiley-Liss.
page 5